203 related articles for article (PubMed ID: 25853236)
1. A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.
Chen CL; Desai-Krieger D; Ortiz S; Kerolous M; Wright HM; Ghahramani P
Am J Ther; 2015; 22(5):e130-40. PubMed ID: 25853236
[TBL] [Abstract][Full Text] [Related]
2. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
Giles TD; Bakris G; Oparil S; Weber MA; Li H; Mallick M; Bharucha DB; Chen C; Ferguson WG;
J Am Soc Hypertens; 2015 Nov; 9(11):845-54. PubMed ID: 26362831
[TBL] [Abstract][Full Text] [Related]
3. Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.
Ishak J; Rael M; Punzi H; Gradman A; Anderson LM; Patel M; Ali S; Ferguson W; Neutel J
J Clin Hypertens (Greenwich); 2018 Jan; 20(1):143-149. PubMed ID: 29105958
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension.
Sander GE; Fernandez C; Giles TD
Expert Rev Cardiovasc Ther; 2016; 14(5):563-72. PubMed ID: 26986445
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.
Jung JA; Noh YH; Jin S; Kim MJ; Kim YH; Jung JA; Lim HS; Bae KS
Clin Ther; 2012 Apr; 34(4):958-65. PubMed ID: 22410289
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension.
Mende CW; Giles TD; Bharucha DB; Ferguson WG; Mallick M; Patel MD
J Clin Hypertens (Greenwich); 2017 Jun; 19(6):632-639. PubMed ID: 28075064
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.
Paton DM
Drugs Today (Barc); 2017 Jan; 53(1):19-26. PubMed ID: 28387384
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
9. Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.
Giles TD; Cockcroft JR; Pitt B; Jakate A; Wright HM
J Hypertens; 2017 Sep; 35(9):1758-1767. PubMed ID: 28509722
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
11. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet.
Battise D; Boland CL; Nuzum DS
Ann Pharmacother; 2019 Apr; 53(4):402-412. PubMed ID: 30449127
[TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
Jung JA; Lee SY; Kim JR; Ko JW; Jang SB; Nam SY; Huh W
Drug Des Devel Ther; 2015; 9():745-52. PubMed ID: 25767372
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
Bindschedler M; Degen P; Flesch G; de Gasparo M; Preiswerk G
Eur J Clin Pharmacol; 1997; 52(5):371-8. PubMed ID: 9272406
[TBL] [Abstract][Full Text] [Related]
16. Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination.
Izzo JL; Khan SU; Saleem O; Osmond PJ
J Am Soc Hypertens; 2015 Jul; 9(7):526-35. PubMed ID: 26116459
[TBL] [Abstract][Full Text] [Related]
17. Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers.
Gheldiu AM; Vlase L; Popa A; Briciu C; Muntean D; Bocsan C; Buzoianu A; Achim M; Tomuta I; Todor I; Neag M
J Pharm Pharm Sci; 2017; 20():68-80. PubMed ID: 28459657
[TBL] [Abstract][Full Text] [Related]
18. Time-Dependent Effects of Individual and Combined Treatments With Nebivolol, Lisinopril, and Valsartan on Blood Pressure and Vascular Reactivity to Angiotensin II and Norepinephrine.
Lezama-Martinez D; Elena Hernandez-Campos M; Flores-Monroy J; Valencia-Hernandez I; Martinez-Aguilar L
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):490-499. PubMed ID: 33779339
[TBL] [Abstract][Full Text] [Related]
19. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers.
Hedaya MA; Helmy SA
Clin Ther; 2013 Jun; 35(6):846-61. PubMed ID: 23795576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
